Restoring Fertilization Readiness At Any Age With Molecular Precision
ZIÖRA develops and commercializes breakthrough fertility technologies enabling clinicians to restore male and female reproductive function and improve IVF access, precision, and outcomes.
ZIÖRA is advancing a portfolio of breakthrough reproductive technologies designed to reinforce every step of fertility care—reducing treatment burden and accelerating access to success.
ADVANCING MULTIPLE BREAKTHROUGHS
Beyond sperm activation, ZIÖRA is developing next-generation technologies that improve gamete quality, strengthen the IVF process, and support fertility longevity across IVF
In partnership with clinicians and the patients they serve, ZIÖRA is not redefining IVF—it’s reinforcing its foundation, synchronizing biology with timing to set a new gold standard for predictable, life-changing outcomes.
MISSION-DRIVEN
Science Guided by Purpose
ZIÖRA’s guiding principle is simple: strength arises from reinforcement.
Rooted in the precision of an ancient Japanese restoration art, ZIÖRA applies that philosophy at the molecular level—closing gaps and restoring alignment between process and biology with precision and timing.
Fertility care continues to advance, yet time’s weight grows heavier for patients and clinicians. ZIÖRA refines where systems, not patients, fall out of sync, extending the biological window of fertility and equipping clinicians with tools that turn potential into measurable outcomes.
Clinicians and partners interested in early data or collaboration please connect.
LEAD INNOVATION
FERTILUX — Engineering Readiness Before Fertilization
FERTILUX, ZIÖRA’s patented innovation, emulates sperm activation in IVF and IUI settings.
As an ex-vivo sperm treatment, it enhances sperm function, achieving a state of hyperactivation, increasing the number of high-quality embryos per cycle and improving pregnancy outcomes in Assisted Reproductive Technology (ART).
Observed advantages:
Stronger fertilization performance and a higher proportion of high-quality euploid blastocysts (HQEBs).
Embryos with superior developmental competence and implantation potential, facilitating transfer prioritization and serving as a quantifiable indicator of laboratory success.
Fewer cycles yielding no viable or high-quality embryos, demonstrating greater reliability in achieving clinically meaningful outcomes.
Proven reproducibility across cohorts and lab conditions with seamless workflow integration—no added complexity or retraining required.
No indications of toxicity or adverse events; maintains biological integrity and procedural safety.
Together, these findings reaffirm ZIÖRA’s focus on improving outcomes before fertilization—where readiness becomes the foundation of every successful treatment.
Next Phase: Human study results in progress.
INTEGRATION SNAPSHOT
A Quick, Simple Procedure
FERTILUX integrates into standard sperm-preparation protocols as a single-step enhancement.
No added equipment, retraining, or workflow disruption—just improved readiness using the same centrifugation and media steps clinics already perform.
ECONOMIC & OPERATIONAL VALUE
Redefining the Economics of Fertility Care
Fertility has become one of the most urgent health and economic challenges of our generation.
ZIÖRA transforms biological alignment into measurable economic value—helping clinics achieve higher success rates, lower costs, and greater scalability.
Ultimately, molecular alignment becomes predictable economic gain.
COST & INEFFICIENCY
Despite decades of progress, IVF remains limited by system-level performance gaps that begin long before embryo transfer.
All cycles require the same time, personnel, and patient investment, yet more than 60% still fail to result in a live birth—forcing clinics to repeat procedures and patients to endure added cost, stimulation, and unnecessary emotional strain.
These are not individual shortcomings; they’re symptoms of a process built on legacy laboratory tools and biological variability that the system has never fully controlled, until now.
$27K
Average U.S. cost per full IVF cycle (CSI + 1 ET + medications)
2.4
Average number of cycles needed to conceive
$64.8K
Total cost per live birth (Average cost per cycle × Average number of cycles to conceive)
CLINICAL OPERATING REALITY
Average Clinic EBITDA Margin ≈ 28% 3
Across fertility medicine, that margin is already the ceiling—not the floor. Clinics already run at full capacity—fixed labs, fixed staff. Every additional cycle consumes identical cost but yields diminishing return.
28% isn’t success—it’s the efficiency limit of biology left unmanaged.
ZIÖRA extends clinical performance by improving gamete readiness at the molecular level—enabling more viable pregnancies per cycle.
For clinics and physicians, the equation is simple: Operational clarity. Financial inevitability. Patient alignment.
In a field with finite infrastructure and compounding demand, precision isn’t a product—it’s margin expansion in molecular form.
ECONOMIC IMPACT AT A GLANCE
Every failed cycle consumes capacity and erodes margin.
~832
Average annual IVF cycles per clinic
5–10 %
Conservative productivity gain with ZIÖRA
$1.5–3M
Annual economic value per clinic unlocked
When precision scales, margins expand - and the path to parenthood finally becomes predictable.
MARKET VALIDATION
A Proven Need. A Global Demand.
Infertility affects 1 in 6 adults worldwide — 17.5% of the world's population.
The global fertility-care market is will reach $41B in 2026, growing 6.1% annually, driven by delayed parenthood, increased awareness, and demands for non-invasive innovation.
In the United States alone, 432,641 IVF cycles take place across 371 reporting SART clinics (~ 1,166 per clinic*), proof of need for biological precision that scales.
Yet even as procedure volume increases, clinic capacity and efficiency remain fixed—creating a widening gap between global demand and operational capability.
*Market data derived from: $34.7 B (2023) → $62.8 B (2033) growth trajectory; SART 2023 Clinic Summary Report.
CLINICAL PAIN POINTS
Clinics Know the Pain Points. ZIÖRA Solves Them.
Global fertility has dropped the lowest in recorded history.
As expectations mount across fertility care, clinicians confront this daily in older patients, complex cases, and rising demand.
<2.3 births per woman
ZIÖRA synchronizes biology, time, and systems—restoring control where predictability has disappeared.
Gamete quality declines across both sexes with age.
Male sperm counts have fallen over 50% since 1973; between ages 30 and 50 years, semen volume declines 3–22%, motility 3–37%, and normal morphology 4–18%.
Female IVF live-birth rates fall from ~41% (< 35 yrs) to ~4% (> 42 yrs), driven by rising embryo aneuploidy—euploid embryos drop from 57% at ≤ 35 yrs to 13% at 44 yrs.
Fertilization now begins from a molecular disadvantage that ZIÖRA is engineered to correct.
LIFE-CHANGING DIFFERENTIATORS
Where Science Becomes Scalability
ZIÖRA technology saves patients >$25K, while shortening the entire journey from fertilization to live birth.
Scientific & Clinical Advantages
Protected Molecular Process
Patented and proprietary pathway for gamete readiness, ensuring scientific defensibility and regulatory clarity.
Extended Fertility Viability
Supports gamete function and timing, expanding the biological window for conception.
Fewer Cycles to Baby*
Most patients require two or more IVF cycles to succeed. Improving first-pass efficiency reduces repeat stimulation and retrievals.*
Shorter Time to Baby
Each IVF cycle takes 6–8 weeks. Higher per-cycle success shortens the path to pregnancy.*
Lower Cost to Baby
Each IVF cycle costs $20K–$30K. Higher per-cycle success reduces total cost per live birth by 20–30%.*
Less Life Disruption to Baby
Each failed cycle adds months of strain. Higher first-pass success reduces physical, emotional, and financial burdens.
Building on value-based IVF frameworks proposed by Sable & Sirius (2021), ZIÖRA aligns biological precision with the true outcomes that matter—babies, not cycles.
*Proven in preclinical animal models
WORKFLOW INTEGRATION
Designed for Adoption, Not Adaptation
FERTILUX integrates directly into existing IVF and IUI workflows—no capital equipment, no retraining, no process disruption.
☑ Applied during the standard sperm-preparation step.
☑ Compatible with both ICSI and conventional insemination.
☑ Adds no additional time to the laboratory schedule.
By enhancing gamete readiness within the workflow clinics already know, ZIÖRA transforms biological precision into operational ease.
“This is showing significant improvement in the number of blastocysts. Really, any improvement is good.”
— Fertility Specialist, UK
“If you can improve quality euploid blasts, you have a 'family building' product in IVF.”
— Reproductive Endocrinologist, Shady Grove, US
“This is brilliant. I’ve never seen anything that focuses on sperm preparation like this!”
— Private Clinic Administrator, France
"With 10% improvement, this would be adopted in my clinic very quickly. With 20%, it would be a crime not to use this product.”
— Public Clinic Administrator, Australia
“One of the good things is the potential in the reduction of IVF cycles.”
— Payer, UK
PIPELINE OF PRECISION
A Pipeline Built to Reinforce Every Step of IVF
EXPERIENCED TEAM
Depth Born From Discovery, Precision Built on Experience
ZIÖRA is led by a multidisciplinary team whose collective experience spans every dimension of modern fertility care—from scientific discovery to commercial scale.
Their backgrounds unite clinical medicine, reproductive biology, biotech innovation, and IVF operations across more than 30 international markets.
Together, they combine deep scientific expertise and global fertility experience—reinforcing IVF’s foundation through science that endures.
Pioneered fertility and IVF programs for leading global life-science companies, launching category-defining products and expanding access worldwide.
Served as C-suite and divisional leaders for top fertility and biotech enterprises—driving the global commercialization of IVF therapeutics.
Built and scaled fertility clinic networks across North America, Europe, and Asia, transforming localized practices into integrated platforms.
Advanced clinical and medical affairs leadership in reproductive medicine, oncology, and endocrinology—bridging molecular science with patient outcomes.
Driven innovation at the intersection of biology, technology, and strategy, from molecular therapeutics to precision diagnostics.
Advised global institutions and health councils shaping the future of reproductive health, longevity, and regenerative medicine.
IN SYNC
The Next Era of Fertility Is Built Together
